1. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
- Author
-
Jean-Louis A. Parmasad, Konrad M. Ricke, Benjamin Nguyen, Morgan G. Stykel, Brodie Buchner-Duby, Amanda Bruce, Haley M. Geertsma, Eric Lian, Nathalie A. Lengacher, Steve M. Callaghan, Alvin Joselin, Julianna J. Tomlinson, Michael G. Schlossmacher, William L. Stanford, Jiyan Ma, Patrik Brundin, Scott D. Ryan, and Maxime W. C. Rousseaux
- Subjects
Cytology ,QH573-671 - Abstract
Abstract Parkinson’s disease (PD) is a debilitating neurodegenerative disease characterized by the loss of midbrain dopaminergic neurons (DaNs) and the abnormal accumulation of α-Synuclein (α-Syn) protein. Currently, no treatment can slow nor halt the progression of PD. Multiplications and mutations of the α-Syn gene (SNCA) cause PD-associated syndromes and animal models that overexpress α-Syn replicate several features of PD. Decreasing total α-Syn levels, therefore, is an attractive approach to slow down neurodegeneration in patients with synucleinopathy. We previously performed a genetic screen for modifiers of α-Syn levels and identified CDK14, a kinase of largely unknown function as a regulator of α-Syn. To test the potential therapeutic effects of CDK14 reduction in PD, we ablated Cdk14 in the α-Syn preformed fibrils (PFF)-induced PD mouse model. We found that loss of Cdk14 mitigates the grip strength deficit of PFF-treated mice and ameliorates PFF-induced cortical α-Syn pathology, indicated by reduced numbers of pS129 α-Syn-containing cells. In primary neurons, we found that Cdk14 depletion protects against the propagation of toxic α-Syn species. We further validated these findings on pS129 α-Syn levels in PD patient neurons. Finally, we leveraged the recent discovery of a covalent inhibitor of CDK14 to determine whether this target is pharmacologically tractable in vitro and in vivo. We found that CDK14 inhibition decreases total and pathologically aggregated α-Syn in human neurons, in PFF-challenged rat neurons and in the brains of α-Syn-humanized mice. In summary, we suggest that CDK14 represents a novel therapeutic target for PD-associated synucleinopathy.
- Published
- 2024
- Full Text
- View/download PDF